ORTHOPEDIATRICS CORP

OrthoPediatrics Corp. announced that its President & CEO, Dave Bailey, and COO & CFO, Fred Hite, are scheduled to participate in a fireside chat. The event will take place at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 9:00 am ET. An audio webcast of the discussion will be accessible on the company's investor relations website, with a replay available afterward.

OrthoPediatrics Corp. announced it will release its second-quarter 2026 financial results on Tuesday, August 4, 2026, after the market closes. The company will host a conference call on the same day at 4:30 p.m. ET to discuss the results. Investors can access a live and archived webcast of the event on the company's website.

OrthoPediatrics Corp. announced an exclusive distribution agreement with OSSIO, Inc. to bring bio-integrative, metal-free fixation technology to U.S. children's hospitals. This OSSIOfiber® technology is designed to be replaced by the patient's newly formed bone, thereby decreasing the need for secondary hardware removal surgeries common with metal implants. The partnership expands OrthoPediatrics' product offering, addresses unmet pediatric needs, and is expected to strengthen the company's long-term growth potential.

OrthoPediatrics Corp. announced that its Chief Operating Officer and Chief Financial Officer, Fred Hite, is scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference. The event will be held on Monday, June 8, 2026, at 2:40 pm ET in Miami Beach, FL. An audio webcast and replay of the discussion will be accessible via the company's investor relations website.

OrthoPediatrics Corp. reported a 13.3% increase in net revenue for Q1 2026, reaching $59.36 million, with a net loss of $(10.69) million, comparable to the prior year. The company completed the acquisition of London Orthotic Consultancy Consolidated Ltd (LOC) for GBP 5.22 million cash and GBP 0.6 million in promissory notes, with potential earnouts. Additionally, OrthoPediatrics amended its Term Loan Agreement to establish a new $20 million delayed draw term loan facility.

OrthoPediatrics Corp. reported Q1 2026 revenue of $59.4 million, a 13% increase year-over-year, with Adjusted EBITDA turning positive at $2.2 million. The company maintained its full-year 2026 revenue guidance of $263.0 million to $267.0 million and expects to achieve breakeven free cash flow. These figures are part of an investor presentation to be used by executive officers.

OrthoPediatrics Corp. reported a strong first quarter for 2026, with total revenue increasing 13% year-over-year to $59.4 million. The company achieved adjusted EBITDA of $2.2 million, a significant improvement from a loss in the prior year, and reduced free cash flow usage by 40%. This performance was driven by robust domestic and international growth across its Trauma & Deformity and Scoliosis segments, leading the company to increase its full-year 2026 revenue guidance.

OrthoPediatrics Corp. (KIDS) announced the launch of its new TRAXIO Complete - Weight System, expanding its OrthoPediatrics Specialty Bracing (OPSB) portfolio. Developed in collaboration with Synetik Group, Inc., TRAXIO is a halo gravity traction system designed for controlled, weight-based axial traction for gradual spinal realignment in pediatric patients within hospital settings. This launch reinforces OrthoPediatrics' commitment to advancing pediatric scoliosis care and strengthens its comprehensive offerings for pediatric spine surgeons.

OrthoPediatrics Corp. announced it will release its first quarter 2026 financial results on Thursday, April 30, 2026, after the market closes. The company will host a conference call on the same day at 4:30 p.m. ET to discuss these results. Investors can access a live and archived webcast of the event on the company's website.